Categories: News

China Pioneers Urban Health-Climate Solutions as Risks Hit Record High, Offers New Pathways for Global South

The new Lancet Countdown China report reveals that 8 of 13 climate-health risk indicators are at historic peaks; the Beijing launch showcases scalable approaches for resilient and low-carbon urban development.

- Advertisement -

BEIJING, Oct. 31, 2025 /PRNewswire/ — As 8 of 13 critical climate-health risk indicators reach record highs in China, the 2025 Lancet Countdown China Report, launched today at Tsinghua University, offers valuable lessons for urban resilience and low-carbon development.

- Advertisement -

Marking World Cities Day under the theme “Empowering Cities for Synergistic Action”, the report delivers unprecedented city-level analysis, revealing a critical gap between national and provincial assessments and the distinct risks faced by individual cities. “While climate red alerts are flashing everywhere, we must fight public desensitization and provide cities with targeted solutions,” said Professor Cai Wenjia, Director of the Lancet Countdown Asia Centre at Tsinghua University. “Our analysis shows health-focused climate action isn’t an economic brake – it’s actually an accelerator for growth.”

- Advertisement -

Key findings with regional implications include:

- Advertisement -
  • Asian countries now experience an average of 20 heatwave days per year (2022-2024), with climate change responsible for 16 of these days
  • Public risk fatigue is emerging as climate warnings become constant, threatening response effectiveness
  • Each city faces its own distinct climate-health crisis – national averages mask critical local vulnerabilities
  • Scientific research doesn’t match cities’ most urgent needs, with cost-effective solutions remaining scarce
  • Health-centered climate action accelerates rather than hinders economic growth

The report identifies cities as both the epicenter of climate health risks and the engine of solutions, outlining five priority actions from developing people-centered early warning systems to embedding health in smart city planning.

- Advertisement -

The launch featured experts from Singapore, India, Australia, and China discussing practical urban solutions. The event also highlighted new financing pathways. The Asian Infrastructure Investment Bank outlined its focus on health- and nature-positive infrastructure, while the Asian Venture Philanthropy Network introduced its Climate x Health Lighthouse Fund—Asia’s first philanthropic fund scaling adaptation innovation.

- Advertisement -

“The city-level evidence in this report is exactly what local governments need to move from planning to action,” said Dr. Sandro Demaio, Director of the WHO Asia-Pacific Centre for Environment and Health.

- Advertisement -

The full report is available at https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00230-0/fulltext 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/china-pioneers-urban-health-climate-solutions-as-risks-hit-record-high-offers-new-pathways-for-global-south-302600855.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

6 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

6 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

6 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

6 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

6 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

6 hours ago